# Assessment of the Effects of Single-Domain Anti-Idiotypic Distribution Enhancers on the Disposition of Trastuzumab and on the Efficacy of a PE24-Trastuzumab Immunotoxin

## TL;DR

Researchers tested how anti-idiotypic distribution enhancers (AIDEs) improve the effectiveness of an antibody-based cancer treatment by enhancing drug distribution in tumors.

## Contribution

The study introduces a novel strategy using AIDEs to enhance the tumor-targeting and efficacy of a potent immunotoxin, supported by mechanistic modeling.

## Key findings

- AIDE coadministration improved the anti-tumor efficacy of trastuzumab–PE24 in xenograft models.
- Modeling predicted that repeated AIDE administration could lead to complete tumor regression.
- AIDEs had minimal negative effects on drug exposure and selectivity.

## Abstract

The efficacy of antibody-based therapies applied to solid tumors is often limited by the “binding-site barrier” (BSB). Our group has developed anti-idiotypic distribution enhancers (AIDEs), which enhance antibody intra-tumoral distribution and efficacy. This study evaluates 1HE and LG1, model anti-trastuzumab AIDEs, and trastuzumab–PE24, a site-specific conjugated immunotoxin with high potency. Mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling was used to investigate relationships between AIDE binding characteristics and effects on antibody distribution and immunotoxin potency. AIDE coadministration led to negligible negative impacts on overall exposure and pharmacokinetic selectivity. Consistent with prior work demonstrating that AIDEs improve intra-tumoral antibody distribution and anti-cancer efficacy, 1HE and LG1 enhanced the anti-tumor efficacy of trastuzumab-PE in NCI-N87 xenografts. In addition, the PK/PD model predicted that the repeated administration of AIDEs with trastuzumab–PE24 could lead to complete tumor regression. This model prediction implies that the benefits of the AIDE approach increase with the increasing potency of immunotoxins.

Background/Objectives: Antibody-based therapies often exhibit limited distribution within solid tumors due to the “binding-site barrier” (BSB). Our group has developed and validated the use of anti-idiotypic distribution enhancers (AIDEs), which transiently block antibody binding, improving intra-tumoral distribution and efficacy. This study evaluated 1HE and LG1, model anti-trastuzumab AIDEs, in combination with trastuzumab–PE24, a highly potent immunotoxin. Methods: The effects of 1HE on the whole-body disposition of radiolabeled trastuzumab were assessed in NCI-N87 tumor-bearing mice. Mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling was employed to explore how AIDE binding kinetics influence antibody intra-tumoral distribution and immunotoxin potency. Trastuzumab–PE24 was developed by site-specific conjugation, enabled by self-splicing split intein, with cytotoxicity tested on various cell lines in vitro. The impact of 1HE and LG1 coadministration on trastuzumab–PE24 efficacy was evaluated in NCI-N87 xenograft-bearing mice. Results: 1HE coadministration decreased trastuzumab tumor maximum concentration, reducing tumor terminal slope by 8% and overall tumor exposure by 2.6%, without negatively affecting selectivity. Modeling predicted the optimal AIDE dissociation rate constant for trastuzumab–PE24 to be between 0.015 and 0.3 h−1. The coadministration of trastuzumab–PE24 with 1HE and LG1 improved anti-tumor efficacy and extended median survival to 60 days (p = 0.0002). Conclusions: AIDE coadministration led to minimal negative impacts on overall tumor exposure, consistent with model simulations. AIDE coadministration improved the efficacy of trastuzumab–PE24 in NCI-N87 xenografts. Modeling further predicted that repeated AIDE administration with trastuzumab–PE24 could induce complete tumor regression. These findings highlight the advantages of the AIDE strategy, particularly when coadministered with highly potent immunotoxins.